![Author ORCID: We display the ORCID iD icon alongside authors names on our website to acknowledge that the ORCiD has been authenticated when entered by the user. To view the users ORCiD record click the icon. [opens in a new tab]](https://chemrxiv.org/engage/assets/public/chemrxiv/images/logos/orcid.png)
Abstract
With no proven therapy against COVID-19, the repurposing of existing drugs is an ongoing exercise. In this context, an antimalarial drug, hydroxychloroquine (HCQ) received immediate stardom when the US-FDA issued an Emergency Use Authorization (EUA) for HCQ against COVID-19 based on the limited clinical study. However, on 17 June 2020, WHO announced the stoppage of the HCQ trial for COVID-19 treatment based on data received from the Solidarity trial and UK's Recovery trials indicating HCQ does not result in the reduction of mortality of hospitalized COVID-19 patients when compared with standard of care. In this context, the present review aims to provide a developmental journey of HCQ including medicinal chemistry highlighting the essential pharmacology and the current studies exploring its effectiveness against COVID-19, and its synthetic advancement.
